Translating Unbound Exposure Across Species

Why Compare Unbound Exposure?

A total plasma concentration combines drug that is unbound with drug associated with plasma proteins and other components. If the unbound fraction differs between species, equal total concentrations do not imply equal unbound concentrations. That distinction matters when comparing exposure across species or relating measured exposure to a pharmacologic effect: under many conditions, unbound drug is more directly available for distribution and interaction with a target.

Binding adjustment is not a universal conversion that makes animal and human data interchangeable. It is a calculation whose interpretation depends on the measured matrix, the stability of binding, distribution to the relevant tissue, and whether the pharmacologic relationship itself is comparable. The objective is to make those assumptions explicit before drawing a translational conclusion.

Definition: For species \(s\), the plasma unbound fraction \(f_{u,p,s}\) is the fraction of total plasma drug concentration that is unbound: \(f_{u,p,s}=C_{u,p,s}/C_{\mathrm{tot},p,s}\). The tissue unbound fraction \(f_{u,t,s}\) is defined analogously for tissue. Both fractions are dimensionless and lie between 0 and 1. Subscripts \(p\) and \(t\) denote plasma and tissue; \(u\) and \(\mathrm{tot}\) denote unbound and total drug.

These definitions require the numerator and denominator to refer to the same species, time, and matrix. For example, a plasma unbound fraction should be applied to a total plasma concentration, not to a whole-blood concentration. Tissue total concentration is often measured in a homogenate; its interpretation can depend on tissue processing and residual blood. Keep those distinctions visible in data tables and calculations.

Converting Total Plasma Exposure

If \(f_{u,p,s}\) is constant over the concentration range and time period of interest, then at each time \(t\), \(C_{u,p,s}(t)=f_{u,p,s}C_{\mathrm{tot},p,s}(t)\). Integrating both sides over time gives a corresponding relationship for area under the concentration-time curve (AUC). The same proportional conversion applies to a concentration such as \(C_{\max}\), provided binding is constant at the concentrations involved.

\mathrm{AUC}_{u,p,s} =\int C_{u,p,s}(t)\,dt =f_{u,p,s}\int C_{\mathrm{tot},p,s}(t)\,dt =f_{u,p,s}\mathrm{AUC}_{\mathrm{tot},p,s}

For two species, the ratio of unbound plasma AUCs is therefore the ratio of total AUCs multiplied by the ratio of unbound fractions:

\frac{\mathrm{AUC}_{u,p,2}}{\mathrm{AUC}_{u,p,1}} = \frac{f_{u,p,2}}{f_{u,p,1}} \frac{\mathrm{AUC}_{\mathrm{tot},p,2}}{\mathrm{AUC}_{\mathrm{tot},p,1}}

This relation is useful only when the fractions are appropriate for the measured concentrations. If binding is concentration-dependent, \(f_{u,p,s}\) can change over a profile. In that case, calculate \(C_{u,p,s}(t)=f_{u,p,s}(t)C_{\mathrm{tot},p,s}(t)\) at each time and integrate the resulting unbound profile; multiplying total AUC by a single fraction may be inaccurate.

Worked Example: Comparing Unbound Plasma AUC

Suppose a hypothetical rat study has a total plasma AUC of \(120\ \mathrm{mg\cdot h/L}\) and \(f_{u,p,\mathrm{rat}}=0.080\). A hypothetical human projection has a total plasma AUC of \(60\ \mathrm{mg\cdot h/L}\) and \(f_{u,p,\mathrm{human}}=0.20\). Assume the fractions are constant over the relevant profiles and the AUCs use the same analyte and plasma matrix.

For rat, the unbound AUC is \(0.080\times120\ \mathrm{mg\cdot h/L}=9.60\ \mathrm{mg\cdot h/L}\). For the human projection, it is \(0.20\times60\ \mathrm{mg\cdot h/L}=12.0\ \mathrm{mg\cdot h/L}\).

The human-to-rat unbound AUC ratio is \(12.0/9.60=1.25\). Although the projected human total AUC is half the rat total AUC, the projected human unbound plasma AUC is 25% higher. This comparison describes exposure, not proof that the pharmacologic effect will be 25% greater: that conclusion would require a justified exposure–effect relationship and comparable pharmacologic sensitivity.

From Plasma to Tissue

A plasma unbound exposure comparison may not represent exposure in a tissue of interest. Define the total tissue-to-plasma concentration ratio as \(K_p=C_{\mathrm{tot},t}/C_{\mathrm{tot},p}\), for concentrations measured at a matched time or under a clearly specified steady-state condition. Define the unbound tissue-to-plasma ratio as \(K_{p,uu}=C_{u,t}/C_{u,p}\). Using the unbound-fraction definitions gives the relationship below.

K_{p,uu} =\frac{C_{\mathrm{tot},t}f_{u,t}}{C_{\mathrm{tot},p}f_{u,p}} =K_p\frac{f_{u,t}}{f_{u,p}}

This identity is a conversion among measured quantities; it does not itself establish the mechanism of tissue distribution. In a simplified case of passive distribution at equilibrium, with no active transport or relevant pH gradient, unbound concentrations may approach equality across plasma and tissue, so \(K_{p,uu}\) is near 1. Under that condition, tissue binding can change the total tissue concentration while leaving unbound tissue concentration similar to unbound plasma concentration. If transport, barriers, pH partitioning, or lack of equilibrium matters, \(K_{p,uu}\) need not be 1.

Worked Example: Tissue Binding and Unbound Concentration

Consider hypothetical matched-time measurements. In rat, total plasma concentration is \(5.0\ \mathrm{mg/L}\), \(f_{u,p}=0.080\), \(K_p=4.0\), and \(f_{u,t}=0.020\). In a human projection, total plasma concentration is \(2.5\ \mathrm{mg/L}\), \(f_{u,p}=0.20\), \(K_p=2.0\), and \(f_{u,t}=0.10\). Assume the tissue measurements are comparable and the fractions apply at these concentrations.

For rat, \(C_{u,p}=5.0\times0.080=0.400\ \mathrm{mg/L}\). Total tissue concentration is \(C_{\mathrm{tot},t}=K_pC_{\mathrm{tot},p}=4.0\times5.0=20.0\ \mathrm{mg/L}\), so \(C_{u,t}=20.0\times0.020=0.400\ \mathrm{mg/L}\). Equivalently, \(K_{p,uu}=4.0\times(0.020/0.080)=1.00\).

For the human projection, \(C_{u,p}=2.5\times0.20=0.500\ \mathrm{mg/L}\). Total tissue concentration is \(2.0\times2.5=5.0\ \mathrm{mg/L}\), giving \(C_{u,t}=5.0\times0.10=0.500\ \mathrm{mg/L}\). Here \(K_{p,uu}=2.0\times(0.10/0.20)=1.00\).

The rat total tissue concentration is four times the projected human value, yet the calculated unbound tissue concentrations are \(0.400\) and \(0.500\ \mathrm{mg/L}\), respectively. In this example, the different total concentrations reflect the combined plasma and tissue binding relationships; they do not indicate greater unbound tissue exposure in rat. The equality of \(K_{p,uu}\) to 1 is consistent with the stated passive-equilibrium simplification, but these arithmetic results alone do not demonstrate that such equilibrium holds biologically.

What Exposure Comparisons Can Say About Effects

Unbound exposure is often a more relevant input to a pharmacologic interpretation than total exposure, but it is not an effect by itself. To translate an exposure comparison into a predicted effect, one must also specify the exposure measure relevant to the response (for example, concentration at a target site or an exposure over time) and justify the exposure–effect relationship. Species differences in target sensitivity or other determinants of response can remain even when unbound exposure is matched.

Worked Example: A Conditional Effect Projection

Suppose the hypothetical tissue calculations above are used with a separately justified, locally linear relationship for an illustrative response: inhibition, in percentage points, equals \(30\ \text{percentage points}/(\mathrm{mg/L})\) multiplied by unbound tissue concentration. Assume the same slope applies in both species over the concentrations shown and that the effect is measured on the same scale.

For rat, predicted inhibition is \(30\ \text{percentage points}/(\mathrm{mg/L})\times0.400\ \mathrm{mg/L}=12.0\) percentage points. For the human projection, it is \(30\ \text{percentage points}/(\mathrm{mg/L})\times0.500\ \mathrm{mg/L}=15.0\) percentage points. The conditional difference is \(15.0-12.0=3.0\) percentage points.

This is a consequence of the assumed shared linear relationship, not of binding data alone. If the slope differs by species, if the relationship is not locally linear, or if the calculated tissue concentration is not the exposure relevant to the response, the numerical effect projection is not justified.

Assumptions, Diagnostics, and Alternatives

Before interpreting a binding-adjusted comparison, check that the quantities being combined are compatible. A useful workflow is to define the intended exposure comparison, confirm the matrix and analyte, assess whether binding is stable over the relevant range, and then calculate the unbound measure. For tissue comparisons, also establish whether tissue concentrations are matched in time or at steady state and whether the measured tissue represents the pharmacologically relevant site.

Check binding measurements. Confirm that the unbound fraction was measured in the relevant species and matrix. Review assay recovery, nonspecific binding, sample handling, and whether the measured range covers the concentrations in the PK profile.
Check concentration dependence. If \(f_u\) changes across concentrations, a single fraction may distort an AUC or peak comparison. Use concentration-specific fractions and reconstruct the unbound profile where data permit.
Check matrix and analyte consistency. Do not apply a plasma fraction to whole-blood concentrations without a justified conversion. Confirm that the compared concentrations refer to the same parent drug or other defined analyte.
Check tissue interpretation. Consider residual blood, tissue homogenate processing, sampling time, and whether the tissue measurement is at distribution equilibrium. A total tissue-to-plasma ratio alone cannot establish unbound target-site exposure.
Check the effect assumption. Similar unbound concentrations do not establish similar effects if the concentration–effect relationship, target sensitivity, or relevant tissue differs between species.

The main alternatives answer different questions. Comparing total plasma exposure is appropriate when total concentration is itself the defined estimand, but it can obscure differences in binding. Comparing unbound plasma exposure adjusts for plasma binding, but may not represent tissue exposure when distribution differs. Comparing unbound tissue exposure is closer to a tissue-site question when it can be estimated reliably, but requires tissue-binding and distribution information that may be uncertain. No single measure is best for every purpose; the choice should match the translational question.

Common pitfall: “The animal has a higher total tissue concentration, so it must have higher pharmacologically available tissue exposure.” This reasoning ignores tissue binding. Calculate \(C_{u,t}=f_{u,t}C_{\mathrm{tot},t}\), and check the plasma-to-tissue relationship as well. A higher total tissue concentration can coexist with equal or lower unbound tissue concentration.

Binding adjustment has limitations even when the arithmetic is correct. Fractions can be imprecise or concentration-dependent; tissue measurements may not represent the target site; and unbound concentrations can vary over time or across compartments. A binding-adjusted exposure ratio therefore should be reported with its assumptions and should not be presented as a direct prediction of clinical response without an appropriate pharmacologic model and evidence for its transportability.

Key takeaway: Convert total to unbound exposure using species- and matrix-specific fractions, and distinguish plasma from tissue. Binding can substantially change total-concentration comparisons; it does not, by itself, establish equal target-site exposure or equal pharmacologic effect.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions.

A hypothetical species has total plasma AUC \(80\ \mathrm{mg\cdot h/L}\) and \(f_{u,p}=0.10\). What is its unbound plasma AUC if binding is constant?
Species A has \(K_p=3.0\), \(f_{u,t}=0.020\), and \(f_{u,p}=0.060\). Calculate \(K_{p,uu}\). What does the result mean?
Why can multiplying total AUC by one unbound fraction be inappropriate when binding is concentration-dependent?
Two species have equal unbound plasma concentrations. Name one reason their unbound tissue concentrations could differ, and one reason their effects could still differ even if unbound tissue concentrations were equal.

Solutions. (1) \(\mathrm{AUC}_{u,p}=0.10\times80=8.0\ \mathrm{mg\cdot h/L}\). (2) \(K_{p,uu}=3.0\times(0.020/0.060)=1.00\), so the calculated unbound tissue and plasma concentrations are equal for the matched condition; this does not prove passive equilibrium. (3) The fraction changes across the profile, so \(C_u(t)=f_u(t)C_{\mathrm{tot}}(t)\) must be calculated over time before integration. (4) Tissue transport, pH partitioning, or failure to reach equilibrium can alter the unbound tissue-to-plasma ratio. Effects may still differ because the species-specific exposure–effect relationship or target sensitivity differs.